Procarbazine
Based on 4 publication(s) in Google Scholar
Procarbazine is an orally active alkylating agent, with anticancer activity. Procarbazine can be used in Hodgkin's disease research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 671-16-9
- Formule: C12H19N3O
- Masse moléculaire:221.30
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Procarbazine
More
Activité biologique
Procarbazine (5 and 20 nM; 1 h) treatment shows cell survival at various concentrarions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:L1210 cells
-
Concentration:5 and 20 nM
-
Incubation Time:1 hour
-
Result:Showed 99.3% and 99.9% survival of cells at 5 mM and 20 mM, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male muta mouse (7-8 weeks old) [2]
-
Dosage:50 and 150 mg/kg
-
Administration:Intraperitoneal injection; 50 and 150 mg/kg; once daily; 5 days
-
Result:Increased the MN frequency appreciably, and observed micronucleus induction in the peripheral blood at 50 mg/kg.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 671-16-9
-
Masse moléculaire 221.30
-
Formule C12H19N3O
-
SMILES
O=C(NC(C)C)C1=CC=C(CNNC)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Mol Imaging Biol
Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23. [Abstract]2020 Feb;22(1):124-133. PMID: 30989436
Pureté et documentation
Références
[1]. J M Erikson, et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res. 1989 Jan 1;49(1):127-33. [Content Brief]
[2]. T Suzuki, et al. Procarbazine genotoxicity in the MutaMouse; strong clastogenicity and organ-specific induction of lacZ mutations. Mutat Res. 1999 Aug 18;444(2):269-81. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Procarbazine Related Classifications
HY-13733A Related Classifications
Powered by Bioz